Search

Your search keyword '"van der Ryst, E."' showing total 42 results

Search Constraints

Start Over You searched for: Author "van der Ryst, E." Remove constraint Author: "van der Ryst, E." Search Limiters Full Text Remove constraint Search Limiters: Full Text
Sorry, I don't understand your search. ×
42 results on '"van der Ryst, E."'

Search Results

1. sj-pdf-1-avc-10.1177_20402066211030380 - Supplemental material for V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

Catalog

Books, media, physical & digital resources

3. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

5. Correlation Among Total Lymphocyte Count, Absolute CD4+ Count, and CD4+ Percentage in a Group of HIV-1-Infected South African Patients

6. Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings

7. Molecular epidemiology of 58 new African T-Cell leukemia virus type 1 (HTLV-1) strains : identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies

9. Randomised placebo-controlled trial to evaluate the effect of vitamin A on mother-to-child transmission of HIV-1 in Bloemfontein

11. Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-1) strains: identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies

14. First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

15. Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.

16. Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

18. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.

19. An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index.

20. Hepatic safety and tolerability in the maraviroc clinical development program.

21. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

22. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

23. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.

24. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

25. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.

26. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

27. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

30. HIV/AIDS-related knowledge, attitudes and practices among South African military recruits.

31. Possible human ehrlichiosis in the Free State.

33. The use of psychiatric rating scales--a note of caution.

34. Usefulness of HIV-1 V3 serotyping in studying the HIV-1 epidemic in South Africa.

35. More cases of invasive Kaposi's sarcoma?

36. Hepatitis D virus--how prevalent?

39. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.

40. Should South Africa be preparing for HIV-1 vaccine efficacy trials?